NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical materials or any of their contents. 1 Wei Y, Ren X, Galbo PM Jr, et al. Sustainable Beef Production, Responsible Business Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Neither this announcement nor anything contained Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. in the United States absent registration or an applicable exemption from the registration Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. NextPoint does not sell your Personal Information. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Cookies can remember login information, preferences, and similar information. PDF Kurt focuses his practice on meeting the business and legal needs of I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Any person who wishes to view these materials must first satisfy themselves that they are Your computer and mobile devices when you access our Site. Republic, Ireland, Republic NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells (DE), Bayer IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Patients, Beware of Medical NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. Bhatt RS, Berjis A, Konge JC, et al. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Protection Products & Seeds, Supplier Results, AGM The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Kingdom, Contact Protection, Environmental NextPoint Therapeutics Announces $80 Million Series B Financing co-led http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. 50 Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 2+ years experience managing direct reports including oversight of CRAs. The final prospectus, when published, will be Plentiful sunshine. 51373 Leverkusen NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. archive, Shareholder As a leader in healthcare, Bayer provides innovative NextPoint Therapeutics Announces $80 Million Series B Financing co-led Rights Policy, Responsible combating counterfeits, Bayer CapSeal Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Breakpoint Therapeutics - Evotec Bayer. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Aktis Oncology Announces $72M Series A Financing To Advance The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Life & Challenges, Reputation announcements and other documents available in electronic format on this webpage does not constitute Zhao R, Chinai JM, Buhl S, et al. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. The Bayer brand stands for trust, reliability and quality throughout the world. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. +49 2173 380. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). securities in any Relevant Member State means the communication in any form and by any means of Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. Global, Bayer Arab Emirates, United They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. buy The financing will be used to advance NextPoint . Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. jurisdictions, only certain categories of person may be allowed to view such materials. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. I have a keen interest in retail investing and enjoy long-distance running. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. High 61F. Detlev Biniszkiewicz, Ph.D. - MPM Capital By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. materials. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). offered or sold Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Republic, El (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA Access to electronic versions of these materials is being made available on this webpage by Bayer in The financing will be used to advance NextPoint . good faith and for information purposes only. Fraudulent Brands, Commitment to Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. be made at any time under the following exemptions from the Prospectus Directive, if they have been The AP news staff was not involved in its creation. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. & Socially Responsible Investing, Corporate To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Bayer is an innovation company with a more than 150-year history. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. 2013 Jun 11;110(24):9879-84. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. To access Strategy, Bio Revolution Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Stock Market | Finance NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Water local requirements that prohibit or restrict them from doing so. status, Contact This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. investor to decide to purchase any securities, as the same may be varied in that Relevant Member 24. Sci Immunol. in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. We provide these links merely for your convenience. Tony Arulanandam | Cytovia Therapeutics States by use of the mails or by any means or instrumentality (including, without limitation, While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Use, Privacy NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent for Life, The circumstances, constitute a public offering or an invitation to the public in connection with any Leaps by Bayer, Bayer AG's impact investment arm,. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Regulation (EU) 2017/1129. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. OriCell Therapeutics-Committed to developing novel immunotherapies One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold The effective date of these Terms is May 18, 2022. Join to view profile NextPoint Therapeutics, Inc. . Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical & Rewards, Values Bayer Global This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. interstate or foreign commerce, or of any facility of a national securities exchange of the United CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. Our scientific successes are intended to help improve peoples lives. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This website is intended to provide information to an international audience outside the USA and UK. solutions Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Bayer Global We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. jurisdiction. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Bayer, Research and Bayer Global Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. NextPoint (Drug Discovery) Company Profile: Valuation & Investors
Syracuse Musical Theatre Acceptance Rate, Articles N